UNSPSC 51152200: Combination neuromuscular blocking agents

This classification denotes combination drugs and preparations that interrupt transmission of nerve impulses at the skeletal neuromuscular junction and which therefore bear the name NEUROMUSCULAR BLOCKING AGENTS. Typical combination neuromuscular blocking agent constituents are mivacurium chloride and dextrose.

UNSPSC 51152200 Combination neuromuscular blocking agents, a Class code, does not align with the state and local procurement activity currently tagged under it. The recent opportunity on file — Seminole County, Florida's IFB for naloxone and drug deactivation systems — concerns emergency response and opioid overdose reversal supplies, not neuromuscular blocking pharmaceutical agents used in anesthesia or critical care. The mismatch suggests either a code assignment error in the source database or a jurisdictional tagging practice that diverges from the UNSPSC taxonomy definition. No additional recent state and local solicitations under this code appear in the dataset.

The single tracked opportunity, IFB 60459723LAS, posted June 30, 2026, with a response deadline of July 26, 2026, at 2:00 pm, calls for 1,900 units of naloxone and 800 drug deactivation systems annually with quarterly deliveries to Seminole County's Community Health Building in Sanford, Florida. The contract includes an initial two-year term with a one-year renewal option, fixed-fee pricing, and standard compliance requirements including E-Verify, drug-free workplace certification, and workers' compensation insurance. Vendors are responsible for all shipping and delivery costs. Given the scope mismatch and limited recent activity, this code warrants manual review for potential reclassification rather than pursuit based on the nominal pharmaceutical classification.